Erasca receives fast track designation for glioblastoma therapy
Pharmaceutical Technology
MAY 2, 2023
The orally bioavailable small molecule EGFR inhibitor ERAS-801 demonstrated significant central nervous system (CNS) penetration in animal trials. This newly granted status helps Erasca to facilitate the development and review of ERAS-801, thereby accelerating the therapy’s reach to patients.
Let's personalize your content